Skip to content
If you’ve been considering peptide therapy, recent headlines may have caught your attention. A new federal announcement could change how certain peptides are made available through licensed compounding pharmacies, potentially opening the door to more personalized treatment options.
But before deciding whether peptide therapy is right for you, it’s important to understand what has actually changed, what questions remain, and what to discuss with your healthcare provider.
At a Glance: What You Should Know
What’s changed: In October 2026, the U.S. Department of Health and Human Services (HHS) announced a draft policy outlining conditions under which certain licensed pharmacies and physicians may compound six specific peptides without facing certain federal enforcement actions.
What hasn’t changed: These peptides are not FDA-approved, and the announcement does not establish that they are safe or effective for any particular condition. The policy is interim, remains subject to further review, and does not remove other legal requirements.
What this means for you: The announcement may create additional treatment options, but availability and medical appropriateness depend on several factors. Understanding the research, potential risks, and your individual health needs is still the most important first step.
What Changed With the New HHS Peptide Announcement?
Peptide therapy has become a growing topic of interest in personalized healthcare, but federal restrictions have limited how certain peptides can be prepared by compounding pharmacies. The latest announcement introduces a possible path forward for six substances that have received significant attention.
On October 28, 2026, HHS announced a draft enforcement discretion policy addressing the compounding of the following peptides:
- BPC-157
- Epitalon
- KPV
- MOTS-c
- Semax
- TB-500
Under the policy, HHS outlines specific conditions for certain licensed pharmacies and physicians preparing medications containing these substances. These include requirements for ingredient sourcing, testing, quality practices, patient-specific prescriptions, and safety reporting.
The goal is to provide a more controlled pathway for certain compounded medications while federal regulators continue reviewing the substances. However, this is not the same as FDA approval or unrestricted permission to offer these treatments.
The policy is still considered a draft and may change as the review process continues. Patients can find additional details in the official Federal Register announcement.
Three Questions to Ask Before Considering Peptide Therapy
The announcement may be encouraging for patients interested in additional treatment options, but a change in federal policy doesn’t automatically mean a treatment is right for you. Before considering peptide therapy, there are three important questions worth discussing with your physician.
1. What Human Research Supports This Treatment?
Not all peptides have the same level of scientific research behind them. While some substances have been studied in laboratory or animal settings, that research doesn’t always tell us how a treatment will work in humans.
Ask your physician what human studies are available for the specific peptide and its proposed use. Understanding what has been studied, what the results show, and where evidence is still limited can help you set realistic expectations.
2. What Risks and Uncertainties Should I Know About?
Every medical treatment comes with considerations, and compounded peptides are no exception. Potential side effects, medication interactions, and long-term safety are important topics to discuss, particularly when human research is limited.
The six peptides included in the HHS announcement are not FDA-approved. As the FDA explains in its guidance on compounded medications, these medications do not undergo FDA review for safety, effectiveness, and quality before being marketed.
A physician can help you understand the known risks, where information is still missing, and whether those uncertainties are reasonable to consider in your situation.
3. How Would a Provider Determine Whether It’s Right for Me?
Personalized care involves more than selecting a treatment based on symptoms or health goals. Your physician should review your medical history, current medications, overall health, and the evidence supporting a particular therapy before making a recommendation.
It’s also worth asking how your progress would be monitored, what follow-up care would involve, and whether other established treatment options may be more appropriate.
A thoughtful treatment plan should include clear expectations, ongoing communication, and the opportunity to ask questions before making a decision.
How Is Evolve Approaching the New Peptide Policy?
At Evolve, we’re encouraged by developments that may create additional opportunities for personalized care. However, our approach to evaluating treatments remains focused on patient safety, available medical evidence, and individual needs.
We work with reputable, licensed compounding pharmacies that we carefully screen for ingredient sourcing, testing, and quality practices. These safeguards help support responsible care, although they do not replace FDA approval or eliminate treatment risks.
As regulations continue to develop, Evolve remains committed to evaluating potential treatment options carefully while maintaining our standards for physician-guided care, clear communication, and ongoing patient support.
When Should You Speak With a Provider?
If you’ve been following the recent peptide announcement, you may be wondering whether any of these developments could affect your current or future care. The best place to start is with a conversation about your individual health needs and the treatment options supported by available evidence.
Your Evolve care team can help answer questions about the recent policy developments and whether scheduling a physician evaluation makes sense for your situation. If an evaluation is appropriate, your provider can discuss your medical history, potential risks, and any next steps.
Have questions about peptide therapy? Contact your Evolve care team to discuss your options and whether a provider evaluation may be appropriate for you.
Frequently Asked Questions
What is the new HHS peptide policy?
In October 2026, HHS announced a draft policy addressing the compounding of six peptides under specific conditions. The policy describes circumstances in which federal regulators do not intend to take certain enforcement actions against qualifying pharmacies and physicians. It does not grant FDA approval.
Which peptides are included in the announcement?
The six peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The policy applies only to specified forms and methods of administration, subject to additional conditions.
Are these six peptides FDA-approved?
No. None of the six peptides has received FDA approval. The policy does not establish that they are safe or effective for any particular medical condition.
Does the new policy mean these peptides are available now?
Not automatically. Availability depends on the policy’s conditions, applicable federal and state requirements, pharmacy eligibility, and individual medical decisions. Patients should confirm availability directly with their healthcare provider.
How do I know whether peptide therapy is appropriate for me?
A qualified physician can review your health history, symptoms, medications, and the available research to determine whether a treatment is appropriate to consider. They can also discuss potential risks, uncertainties, and alternative options.
Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. The regulatory status and availability of compounded medications may change. Always consult a qualified healthcare provider before making treatment decisions.
